Immune Checkpoint Inhibitors

Global Market Trajectory & Analytics

MCP12532

EXECUTIVE ENGAGEMENTS

* Login for a full stack data experience

DATE

APR 2021

TABLES

74

146

EDITION

8

PRICE

USD 4950

CODE

MCP12532

*Engagement stats are ongoing and dynamic

COMPETITIVE METRICS

	COMPANY	D S N T % *
	AstraZeneca PLC
	Bristol-Myers Squibb Company
	Eli Lilly and Company
	EpicentRx Inc
	F. Hoffmann-La Roche AG
	Fortress Biotech, Inc.
	GeneMedicine
	IGNITE Immunotherapy
	Immodulon Therapeutics Ltd.
	ImmuniT Research Inc.

SUBMIT

Note: Best viewed in Landscape Mode

RESEARCH MODULES MARKET TRENDS EXECUTIVES

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Immune Checkpoint Inhibitors estimated at US$14.6 Billion in the year 2020, is projected to reach a revised size of US$50.7 Billion by 2027, growing at a CAGR of 19.4% over the analysis period 2020-2027. CLTA-4 Inhibitors, one of the segments analyzed in the report, is projected to record a 19.7% CAGR and reach US$10.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the PD-1 segment is readjusted to a revised 18.5% CAGR for the next 7-year period.

The Immune Checkpoint Inhibitors market in the U.S. is estimated at US$4.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.4 Billion by the year 2027 trailing a CAGR of 16.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.6% and 17.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR.

In the global PD-L1 Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 22.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.7 Billion in the year 2020 will reach a projected size of US$7.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.4 Billion by the year 2027.

SELECT PLAYERS

AstraZeneca PLC; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche AG; Fortress Biotech, Inc.; Immutep Ltd.; Merck & Co., Inc.; Merck KGaA; Novartis International AG; Pfizer, Inc.

SEGMENTS

» Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, Other Applications) » Drug Class (CLTA-4 Inhibitors, PD-1, PD-L1 Inhibitors)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

World Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027

World Current & Future Analysis for CLTA-4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for CLTA-4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

World Current & Future Analysis for PD-1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for PD-1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

World Current & Future Analysis for PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

World Current & Future Analysis for Bladder cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Bladder cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

World Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

World Current & Future Analysis for Hodgkin lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Hodgkin lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES

USA Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

USA 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

USA Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

USA 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

CANADA

Canada Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Canada 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

Canada Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Canada 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

JAPAN

Japan Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Japan 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

Japan Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Japan 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

CHINA

China Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

China 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

China Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

China 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

EUROPE

Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR

Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027

Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

FRANCE

France Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

France 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

France Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

France 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

GERMANY

Germany Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Germany 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

Germany Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Germany 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

ITALY

Italy Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Italy 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

Italy Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Italy 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

UNITED KINGDOM

UK Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

UK 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

UK Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

UK 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

REST OF EUROPE

Rest of Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Rest of Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

Rest of Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Rest of Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

ASIA-PACIFIC

Asia-Pacific Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Asia-Pacific 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

Asia-Pacific Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Asia-Pacific 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

REST OF WORLD

Rest of World Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Rest of World 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027

Rest of World Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Rest of World 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027

IV. COMPETITION

Total Companies Profiled: 42

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.